Jefferies Reiterates Buy on TeamHealth Holdings (TMH) Following CEO Appointment

September 7, 2016 8:45 AM EDT
Get Alerts TMH Hot Sheet
Price: $43.45 +0.09%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade TMH Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies reiterated a Buy rating and $47.00 price target on TeamHealth Holdings (NYSE: TMH) following the company's appointment of Leif Murphy as President & CEO. Given the CEO appointment, Jefferies views the potential sale of TMH as unlikely in the near-term, and believes that TMH's recent valuation included little or no takeout premium.

Analyst Brian Tanquilut commented, "We view the appointment of Leif Murphy as President & CEO positively given his success in growing and helping to sell DSI Renal, his turnaround capabilities demonstrated as CFO of LPNT, and his excellent business development track record. We acknowledge that the appointment renders the sale of TMH as unlikely in the near-term, but believe Murphy's incentives are structured to ultimately turnaround the company and possibly pursue a sale 1-2 years down the road."

For an analyst ratings summary and ratings history on Team Health click here. For more ratings news on Team Health click here.

Shares of Team Health closed at $34.69 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Changes

Related Entities

Jefferies & Co

Add Your Comment